http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 26 May 2026 08:25:29 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+receives+Johns+Hopkins+approval+for+CMND-100+trial+parts/26546393.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) received approval from the Johns Hopkins Medicine Institutional Review Board to advance its Phase I/II clinical trial of CMND-100 to Parts B and C, the company announced May 26.</p><p>The multicenter study examines single and multiple dose tolerability, safety and pharmacokinetics of CMND-100 in healthy volunteers and subjects with alcohol use disorder. The approval permits the company to proceed with the next phases of the trial following completion of earlier stages.</p><p>CMND-100 is described as a non-hallucinogenic compound based on MEAI being developed as a treatment for alcohol use disorder. The drug candidate is part of what http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+receives+Johns+Hopkins+approval+for+CMND-100+trial+parts/26546393.html Tue, 26 May 2026 08:25:29 -0400 CMND CWY0 http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+receives+Johns+Hopkins+approval+for+CMND-100+trial+parts/26546393.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) received approval from the Johns Hopkins Medicine Institutional Review Board to advance its Phase I/II clinical trial of CMND-100 to Parts B and C, the company announced May 26.</p><p>The multicenter study examines single and multiple dose tolerability, safety and pharmacokinetics of CMND-100 in healthy volunteers and subjects with alcohol use disorder. The approval permits the company to proceed with the next phases of the trial following completion of earlier stages.</p><p>CMND-100 is described as a non-hallucinogenic compound based on MEAI being developed as a treatment for alcohol use disorder. The drug candidate is part of what http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+receives+Johns+Hopkins+approval+for+CMND-100+trial+parts/26546393.html Tue, 26 May 2026 08:25:29 -0400 CMND CWY0 http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html <p>Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) has granted approval for its ongoing Phase I/II clinical trial of CMND-100.</p> <p>The approval advances the multicenter study titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A, B, and http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Johns+Hopkins+IRB+Approval+to+Advance+CMND-100+Phase+III+Clinical+Trial+to+the+Next+Parts/26546389.html Tue, 26 May 2026 08:25:00 -0400 A.37422324 CMND CWY0 O.21095532 O.40363429 http://www.streetinsider.com/Stock+Splits/Clearmind+Medicine+announces+1-for-10+reverse+stock+split+effective+May+21/26516432.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) announced a 1-for-10 reverse stock split of its common shares, effective May 21, 2026. The biotech company said the action is part of its plan to regain compliance with Nasdaq's minimum bid price requirement.</p> <p>The reverse split was approved by the company's board of directors on March 18, 2026, according to a press release. Following implementation, Clearmind's outstanding common shares will decrease from 10,190,337 shares to approximately 1,019,033 shares, subject to adjustments for fractional shares.</p> <p>No fractional shares will be issued, with all fractional shares rounded up to the nearest whole share. The company will make proportionate http://www.streetinsider.com/Stock+Splits/Clearmind+Medicine+announces+1-for-10+reverse+stock+split+effective+May+21/26516432.html Tue, 19 May 2026 06:00:27 -0400 CMND CWY0 O.40363429 http://www.streetinsider.com/Stock+Splits/Clearmind+Medicine+announces+1-for-10+reverse+stock+split+effective+May+21/26516432.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) announced a 1-for-10 reverse stock split of its common shares, effective May 21, 2026. The biotech company said the action is part of its plan to regain compliance with Nasdaq's minimum bid price requirement.</p> <p>The reverse split was approved by the company's board of directors on March 18, 2026, according to a press release. Following implementation, Clearmind's outstanding common shares will decrease from 10,190,337 shares to approximately 1,019,033 shares, subject to adjustments for fractional shares.</p> <p>No fractional shares will be issued, with all fractional shares rounded up to the nearest whole share. The company will make proportionate http://www.streetinsider.com/Stock+Splits/Clearmind+Medicine+announces+1-for-10+reverse+stock+split+effective+May+21/26516432.html Tue, 19 May 2026 06:00:27 -0400 CMND CWY0 O.40363429 http://www.streetinsider.com/Stock+Splits/Clearmind+Medicine+announces+1-for-10+reverse+stock+split+effective+May+21/26516432.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) announced a 1-for-10 reverse stock split of its common shares, effective May 21, 2026. The biotech company said the action is part of its plan to regain compliance with Nasdaq's minimum bid price requirement.</p> <p>The reverse split was approved by the company's board of directors on March 18, 2026, according to a press release. Following implementation, Clearmind's outstanding common shares will decrease from 10,190,337 shares to approximately 1,019,033 shares, subject to adjustments for fractional shares.</p> <p>No fractional shares will be issued, with all fractional shares rounded up to the nearest whole share. The company will make proportionate http://www.streetinsider.com/Stock+Splits/Clearmind+Medicine+announces+1-for-10+reverse+stock+split+effective+May+21/26516432.html Tue, 19 May 2026 06:00:27 -0400 CMND CWY0 O.40363429 http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html <p align="justify">Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing May 21, 2026.</p> http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html Tue, 19 May 2026 06:00:00 -0400 CMND CWY0 O.40363429 http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html <p align="justify">Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing May 21, 2026.</p> http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html Tue, 19 May 2026 06:00:00 -0400 CMND CWY0 O.40363429 http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html <p align="justify">Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing May 21, 2026.</p> http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html Tue, 19 May 2026 06:00:00 -0400 CMND CWY0 O.40363429 http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html <p align="justify">Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing May 21, 2026.</p> http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html Tue, 19 May 2026 06:00:00 -0400 CMND CWY0 O.40363429 http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html <p align="justify">Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing May 21, 2026.</p> http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html Tue, 19 May 2026 06:00:00 -0400 CMND CWY0 O.40363429 http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html <p align="justify">Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing May 21, 2026.</p> http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+1-for-10+Reverse+Share+Split/26516420.html Tue, 19 May 2026 06:00:00 -0400 CMND CWY0 O.40363429 http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+signs+research+deal+to+study+MEAI+with+tirzepatide/26510867.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) announced it has signed a research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem to fund a preclinical study examining MEAI in combination with tirzepatide for obesity treatment.</p> <p>The 12-month study will evaluate the metabolic effects of MEAI (CMND-100) when used alongside tirzepatide and as a maintenance therapy following tirzepatide treatment in diet-induced obese mice. Professor Joseph Tam and his team at the Obesity and Metabolism Laboratory at Hebrew University will conduct the research.</p> <p>The study aims to examine potential additive effects when MEAI is administered with tirzepatide and assess MEAI's ability to http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+signs+research+deal+to+study+MEAI+with+tirzepatide/26510867.html Mon, 18 May 2026 08:42:17 -0400 A.27702406 A.50214885 CMND CWY0 O.13812231 O.22562966 O.40363429 http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+signs+research+deal+to+study+MEAI+with+tirzepatide/26510867.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) announced it has signed a research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem to fund a preclinical study examining MEAI in combination with tirzepatide for obesity treatment.</p> <p>The 12-month study will evaluate the metabolic effects of MEAI (CMND-100) when used alongside tirzepatide and as a maintenance therapy following tirzepatide treatment in diet-induced obese mice. Professor Joseph Tam and his team at the Obesity and Metabolism Laboratory at Hebrew University will conduct the research.</p> <p>The study aims to examine potential additive effects when MEAI is administered with tirzepatide and assess MEAI's ability to http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+signs+research+deal+to+study+MEAI+with+tirzepatide/26510867.html Mon, 18 May 2026 08:42:17 -0400 A.27702406 A.50214885 CMND CWY0 O.13812231 O.22562966 O.40363429 http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+signs+research+deal+to+study+MEAI+with+tirzepatide/26510867.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) announced it has signed a research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem to fund a preclinical study examining MEAI in combination with tirzepatide for obesity treatment.</p> <p>The 12-month study will evaluate the metabolic effects of MEAI (CMND-100) when used alongside tirzepatide and as a maintenance therapy following tirzepatide treatment in diet-induced obese mice. Professor Joseph Tam and his team at the Obesity and Metabolism Laboratory at Hebrew University will conduct the research.</p> <p>The study aims to examine potential additive effects when MEAI is administered with tirzepatide and assess MEAI's ability to http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+signs+research+deal+to+study+MEAI+with+tirzepatide/26510867.html Mon, 18 May 2026 08:42:17 -0400 A.27702406 A.50214885 CMND CWY0 O.13812231 O.22562966 O.40363429 http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+signs+research+deal+to+study+MEAI+with+tirzepatide/26510867.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) announced it has signed a research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem to fund a preclinical study examining MEAI in combination with tirzepatide for obesity treatment.</p> <p>The 12-month study will evaluate the metabolic effects of MEAI (CMND-100) when used alongside tirzepatide and as a maintenance therapy following tirzepatide treatment in diet-induced obese mice. Professor Joseph Tam and his team at the Obesity and Metabolism Laboratory at Hebrew University will conduct the research.</p> <p>The study aims to examine potential additive effects when MEAI is administered with tirzepatide and assess MEAI's ability to http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+signs+research+deal+to+study+MEAI+with+tirzepatide/26510867.html Mon, 18 May 2026 08:42:17 -0400 A.27702406 A.50214885 CMND CWY0 O.13812231 O.22562966 O.40363429